Biopharmaceuticals Market Revenue to Cross $700 Billion by 2028 – Growth Report by The Insight Partners
NEW YORK, UNITED STATES, UNITED STATES, April 4, 2023 /EINPresswire.com/ -- The market for biopharmaceuticals has grown rapidly in recent years, driven by increasing demand for effective and targeted therapies, as well as advances in biotechnology and drug development. Biopharmaceuticals have several advantages over traditional small-molecule drugs, including higher specificity, better efficacy, and lower toxicity.
The biopharmaceuticals market1 includes a range of products, including monoclonal antibodies, recombinant proteins, vaccines, and cell and gene therapies. Some of the largest biopharmaceutical companies in the world include Amgen, Roche/Genentech, Novo Nordisk, and Biogen.
Get Sample Report at https://www.theinsightpartners.com/sample/TIPRE00029847
According to the National Institute of Health (NIH) report, 30 million Americans, accounting for 10% of the population, have one of the ~7,000 known rare diseases. Developing medicines for treating these rare diseases presents, both, scientific and operational challenges. Complex biology associated with rare diseases presents challenges for scientists to design and implement new drug development programs. However, despite these challenges, biopharmaceutical researchers in the Americas have developed new technologies for treating rare diseases and developing groundbreaking therapies. These advancements include the development of groundbreaking therapies such as hemophilia A, spinal muscular atrophy, juvenile idiopathic arthritis, inherited retinal diseases, and transthyretin amyloid cardiomyopathy by biopharmaceutical researchers. Moreover, in the last decade, 350 orphan drugs have been approved by USFDA, particularly for conditions lacking treatment or having limited treatment options.
Global Biopharmaceuticals Market – Growth Scope
Growth rate - CAGR of 13.4% from 2022 to 2028
Market Size Value in - US$ 3,29,966.22 million in 2022
Market Size Value by - US$ 7,00,873.94 million by 2028
Forecast Period - 2022-2028
Base Year - 2022
No. of Pages - 346
No. of Tables - 273
No. of Charts & Figures - 111
Historical data available - Yes
Segments covered - Product Type, and Application
Potential to Treat Rare Diseases to Drive Global Biopharmaceuticals Market Growth:
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a life-threatening, progressive cardiovascular rare disease characterized by the abnormal functioning of the heart, causing infiltrative cardiomyopathy. Once diagnosed, the median life expectancy is only ~2.5–3.5 years, if left untreated. In 2019, the FDA approved Tafamidis for reducing cardiovascular mortality and cardiovascular-related hospitalizations among adults suffering from ATTT-CM. Until 2019, there were no recent advancements in treatment modalities and medicines approved for treating ATTR-CM. A long-term study completed in 2021 reveals that patients continuously administering Tafamidis had a median survival of ~5.5 years.
Speak to Our Analyst at https://www.theinsightpartners.com/speak-to-analyst/TIPRE00029847?utm_source=EINPressWire&utm_medium=10051
Further, biopharmaceutical company Ultragenyx Pharmaceutical Inc. is engaged in the safety testing and dosage determination of molecules developed to treat Glycogen Storage Disease (GSD) type 3, a serious rare and ultra-genetic disease. The company initiated the clinical studies of UX053 in December 2021 to launch it as the first potential medicine for treating patients living with GSD3. The UX053 mRNA can deliver large genes to targeted cells for achieving a high uniformity of protein expression.
Top Listed Players in Biopharmaceuticals Market:
Amgen Inc., Johnson & Johnson, Thermo Fisher Scientific, Abbvie Inc., Eli Lilly And Company, AGC biologics, Wuxi biologics, Bristol-Myers Squibb Company, Boehringer Ingelheim Ltd., and Lonza are among the leading companies operating in the biopharmaceuticals market.
Global biopharmaceuticals market is segmented by region into North America, Europe, Asia Pacific, the Middle East & Africa, and South & Central America. North America held the largest market share of the biopharmaceuticals market in 2022. With several North American market players focusing on research and development activities in the field of imaging technology, the regional market for biopharmaceuticals market is likely to propel in North America region during the forecast period.
Direct Purchase Report on Biopharmaceuticals Market at https://www.theinsightpartners.com/buy/TIPRE00029847
About Us:
The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials.
Contact Us:
If you have any queries about this report or if you would like further information, please contact us:
Contact Person: Sameer Joshi
E-mail: sales@theinsightpartners.com
Phone: +1-646-491-9876
Sameer Joshi
The Insight Partners
+91 96661 11581
email us here
Visit us on social media:
Facebook
Twitter
LinkedIn
1 https://www.theinsightpartners.com/reports/biopharmaceuticals-market
2 https://www.theinsightpartners.com/sample/TIPRE00029847?utm_source=EINPressWire&utm_medium=10051
3 https://www.theinsightpartners.com/buy/TIPRE00029847?utm_source=EINPressWire&utm_medium=10051
![](https://www.einpresswire.com/tracking/article.gif?t=4&a=lbHn_1Eza4rEi7dm&i=z07lPAbNLR297qXs)